close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Drug shortages negatively affecting patient safety, costs of care

Drug shortages negatively affecting patient safety, costs of care

October 1, 2004 -- A study published in the October 1, 2004 issue of the American Journal of Health-System Pharmacy finds that ongoing drug shortages are having far-ranging, negative effects on patient care and hospital costs.

The survey, which is the first formal research to gauge the effect of drug shortages on patient care, polled close to 1,500 pharmacy directors in U.S. health systems. The study revealed that 95 percent of respondents believe shortages have created roadblocks and hurdles for treating patients with the best medication. Sixty-one percent believe the scarcity of certain drugs has compromised patient care. The survey was conducted by the American Society of Health-System Pharmacists (ASHP) and pharmacy residents at Johns Hopkins Hospital, Baltimore, in March 2003.

"Patients are at risk when a needed drug is not available or when health care providers must work with substitute medications," said Henri R. Manasse, Jr., Ph.D., Sc.D., ASHP executive vice president and CEO. "This public health issue must be addressed."

Pharmacy directors reported that drug shortages have affected patients in a number of ways, including contributing to the delay or cancellation of certain medical procedures, prolonged patient stays in hospitals, and serious medication errors.

Shortages have also affected drug prices as pharmacists are forced to buy the same product at higher than contracted prices or more-expensive alternative products in the same therapeutic class. Survey respondents reported that shortages force their hospitals to spend an annual average of $20,000 more in incremental drug purchasing costs. On a national level, this extrapolates to $99,260,000 in additional costs to the U.S. health care system each year. These figures do not take into account the significant personnel time required to manage shortages.

"Drug shortages have been a fact of life in our hospitals and health systems for almost a decade," said study co-author David R. Witmer, Pharm.D., ASHP's vice president of member services. "Because of shortages, pharmacists must select and purchase substitute products as well as determine proper dosing regimens, modify drug-use policies and procedures, educate various health care personnel, and restock the supplies through the facility. All of these extra steps increase risk and add unnecessary costs to the health system."

According to the survey, pharmacists are spending more time managing shortages, including tracking product availability; identifying therapeutic alternatives; contracting with vendors, manufacturers, and group purchasing organizations to buy therapeutic alternatives; and preparing written communications and training other health care providers on using other medications.

ASHP has worked for years to help health-system pharmacists deal with the problem of drug shortages, including launching a Drug Shortages Resource Center (www.ashp.org/shortage) that provides timely reports on medications in short supply as well as their therapeutic alternatives. Eighty-six percent of survey respondents reported using the information provided by the center.

The Society co-sponsored a conference with the American Medical Association in 2002 to identify solutions to the endemic problems that cause shortages in the U.S. pharmaceutical supply chain. In addition, ASHP has developed guidelines for managing drug product shortages. The Society also has adopted a policy position urging the Food and Drug Administration to broaden its term of "medically necessary" drugs so that manufacturers would be required to provide notification of discontinuations for a broader array of products.

For more information on the report, "National Survey of the Impact of Drug Shortages in Acute Care Hospitals," go to www.ashp.org/public/pubs/ajhp. To access the article, use the following login ID and password: ashppr.

For more than 60 years, ASHP has helped pharmacists who practice in hospitals and health systems improve medication use and enhance patient safety. The Society's 30,000 members include pharmacists and pharmacy technicians who practice in inpatient, outpatient, home-care, and long-term-care settings, as well as pharmacy students. For more information about the wide array of ASHP activities and the many ways in which pharmacists help people make the best use of medicines, visit ASHP's Web site, www.ashp.org, or its consumer Web site, www.SafeMedication.com

Source: American Society of Health-System Pharmacists (ASHP)

www.ashp.org/shortage/index.cfm

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...